Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.34), $3.55 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $0 versus the consensus estimate of $191.77 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.